BioSpace News Archive

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that its management will participate at the following conferences.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), today announced that management plans to present and host investor meetings at the Stifel 2021 Virtual Healthcare Conference.

Cerus Corporation announced financial results for the third quarter ended September 30, 2021.

Arcus Biosciences, Inc., a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, announced that the company will report its financial results and a corporate update for the third quarter ended September 30, 2021 after the market closes on Monday, November 8, 2021.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will release third quarter 2021 financial results on Tuesday, November 9, 2021 after the close of market.

Exelixis, Inc. reported financial results for the third quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at three upcoming virtual investor conferences:

Centene Corporation (NYSE: CNC) announced today it will present at the Bernstein Second Annual Operational Decisions Conference, to be held November 3-4, 2021 .

Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the closing of its underwritten initial public offering of 3,600,000 units, each consisting of one share of common stock and one warrant to purchase a share of common stock, at a public offering price per unit of $5.00.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately.